MA24342A1 - Nouvelle modification du cristal de cdch, procede pour sa preparation et formules pharmaceutiques comprenant cette modification - Google Patents

Nouvelle modification du cristal de cdch, procede pour sa preparation et formules pharmaceutiques comprenant cette modification

Info

Publication number
MA24342A1
MA24342A1 MA24398A MA24398A MA24342A1 MA 24342 A1 MA24342 A1 MA 24342A1 MA 24398 A MA24398 A MA 24398A MA 24398 A MA24398 A MA 24398A MA 24342 A1 MA24342 A1 MA 24342A1
Authority
MA
Morocco
Prior art keywords
modification
cdch
crystal
preparation
novel
Prior art date
Application number
MA24398A
Other languages
English (en)
French (fr)
Inventor
Grunenberg Alfous
Bosche Apotheker Patrick
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7779831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA24342(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA24342A1 publication Critical patent/MA24342A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA24398A 1995-12-12 1996-11-22 Nouvelle modification du cristal de cdch, procede pour sa preparation et formules pharmaceutiques comprenant cette modification MA24342A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19546249A DE19546249A1 (de) 1995-12-12 1995-12-12 Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
MA24342A1 true MA24342A1 (fr) 1998-07-01

Family

ID=7779831

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24398A MA24342A1 (fr) 1995-12-12 1996-11-22 Nouvelle modification du cristal de cdch, procede pour sa preparation et formules pharmaceutiques comprenant cette modification

Country Status (42)

Country Link
US (1) US5849752A (enFirst)
EP (1) EP0780390B1 (enFirst)
JP (1) JP4104687B2 (enFirst)
KR (1) KR100525146B1 (enFirst)
CN (1) CN1061348C (enFirst)
AR (1) AR005009A1 (enFirst)
AT (1) ATE221531T1 (enFirst)
AU (1) AU708006B2 (enFirst)
BG (1) BG62258B1 (enFirst)
BR (1) BR9605968A (enFirst)
CA (1) CA2192418C (enFirst)
CO (1) CO4480105A1 (enFirst)
CU (1) CU22774A3 (enFirst)
CZ (1) CZ288657B6 (enFirst)
DE (2) DE19546249A1 (enFirst)
DK (1) DK0780390T3 (enFirst)
EE (1) EE03474B1 (enFirst)
ES (1) ES2179910T3 (enFirst)
HR (1) HRP960558B1 (enFirst)
HU (1) HU226521B1 (enFirst)
ID (1) ID22625A (enFirst)
IL (1) IL119795A (enFirst)
IN (1) IN185805B (enFirst)
MA (1) MA24342A1 (enFirst)
MY (1) MY117492A (enFirst)
NL (1) NL300109I1 (enFirst)
NO (1) NO306725B1 (enFirst)
NZ (1) NZ299905A (enFirst)
PL (1) PL184885B1 (enFirst)
PT (1) PT780390E (enFirst)
RO (1) RO119782B1 (enFirst)
RU (1) RU2162468C2 (enFirst)
SA (1) SA96170492B1 (enFirst)
SG (1) SG47201A1 (enFirst)
SI (1) SI0780390T1 (enFirst)
SK (1) SK282805B6 (enFirst)
SV (1) SV1996000109A (enFirst)
TR (1) TR199600970A2 (enFirst)
TW (1) TW411340B (enFirst)
UA (1) UA35638C2 (enFirst)
YU (1) YU49485B (enFirst)
ZA (1) ZA9610405B (enFirst)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1017392T1 (en) * 1997-09-25 2002-12-31 Bayer Aktiengesellschaft Medicament formulation with a controlled release of an active agent
DE19751948A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AU745282B2 (en) * 1998-11-10 2002-03-21 Bayer Intellectual Property Gmbh Pharmaceutical moxifloxacin preparation
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) * 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
US20060252789A1 (en) * 2002-10-31 2006-11-09 Sujay Biswas Amorphous moxifloxacin hydrochloride
CA2521398C (en) † 2003-04-09 2011-03-22 Dr. Reddy's Laboratories Limited A crystalline form iii of anhydrous moxifloxacin hydrochloride and a process for preparation thereof
WO2005012285A1 (en) * 2003-08-05 2005-02-10 Matrix Laboratories Ltd An improved process for the preparation of moxifloxacin hydrochloride
DE602004018370D1 (de) * 2003-11-20 2009-01-22 Chemi Spa Polymorphe von 1-cyclopropyl-7-(äs,sü - 2,8-diazadicyclo ä4.3.0ü non-8-yl) -6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäurehydrochlorid und verfahren zu deren herstellung
ITMI20032259A1 (it) 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
DE102004015981A1 (de) * 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
ATE446946T1 (de) 2006-06-27 2009-11-15 Sandoz Ag Neues verfahren zur salzherstellung
ES2303768B1 (es) * 2006-09-08 2009-06-05 Quimica Sintetica, S.A. Nueva forma cristalina de moxifloxacino clorhidrato.
KR20150048920A (ko) 2006-11-13 2015-05-07 씨아이피엘에이 엘티디. 목시플록사신 염산염의 합성방법
EP1992626A1 (en) * 2007-05-10 2008-11-19 Sandoz AG Process for the preparation of moxifloxacin hydrochloride
EP2083010A1 (en) * 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
US8314122B2 (en) 2008-10-09 2012-11-20 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of organic solvents in wet granulation of moxifloxacin
WO2010052726A1 (en) * 2008-11-06 2010-05-14 Hetero Research Foundation Novel polymorph of moxifloxacin hydrochloride
EP2735307A1 (de) 2008-12-08 2014-05-28 Ratiopharm GmbH Kompaktiertes Moxifloxacin
CN102459169B (zh) 2009-05-15 2014-12-31 莱德克斯制药有限公司 氧化还原药物衍生物
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN102924449B (zh) * 2012-10-30 2015-08-12 重庆福安药业集团庆余堂制药有限公司 盐酸莫西沙星h晶型及其制备方法和药物组合物
WO2014087292A1 (en) 2012-12-04 2014-06-12 Mankind Research Centre An improved process for the preparation of moxifloxacin hydrochloride
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
WO2014152332A1 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601567A1 (de) * 1986-01-21 1987-07-23 Bayer Ag 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate
CN1019114B (zh) * 1986-03-31 1992-11-18 三共株式会社 喹啉-3-羟酸衍生物的制备方法
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
TW209865B (enFirst) 1992-01-10 1993-07-21 Bayer Ag
ATE207479T1 (de) * 1992-01-31 2001-11-15 Chugai Pharmaceutical Co Ltd Kristalle von derivaten von chinozon carbonsäure- hydraten
DE4234078A1 (de) 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
CA2112165C (en) * 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
ZA946853B (en) * 1993-09-10 1995-04-24 Daiichi Seiyaku Co Crystals of antimicrobial compound.
ATE170400T1 (de) * 1994-04-07 1998-09-15 Pfizer Verwendung von trovafloxacin oder dessen derivaten zur herstellung eines arzneimittels zur behandlung von h.pylori infektionen

Also Published As

Publication number Publication date
YU65096A (sh) 1998-12-23
EP0780390B1 (de) 2002-07-31
TW411340B (en) 2000-11-11
ATE221531T1 (de) 2002-08-15
BR9605968A (pt) 1998-08-18
ID22625A (id) 1999-12-02
IL119795A0 (en) 1997-03-18
DE59609501D1 (de) 2002-09-05
EE9600201A (et) 1997-06-16
JPH09169757A (ja) 1997-06-30
HU9603428D0 (en) 1997-01-28
CO4480105A1 (es) 1997-07-09
HRP960558A2 (en) 1998-02-28
PL317415A1 (en) 1997-06-23
US5849752A (en) 1998-12-15
KR100525146B1 (ko) 2006-01-27
HRP960558B1 (en) 2002-04-30
HUP9603428A2 (en) 1997-08-28
AU708006B2 (en) 1999-07-29
BG62258B1 (bg) 1999-06-30
MY117492A (en) 2004-07-31
CA2192418C (en) 2001-06-12
UA35638C2 (uk) 2001-04-16
DK0780390T3 (da) 2002-11-11
DE19546249A1 (de) 1997-06-19
SG47201A1 (en) 1998-03-20
YU49485B (sh) 2006-08-17
ES2179910T3 (es) 2003-02-01
SK159196A3 (en) 1997-10-08
SA96170492B1 (ar) 2006-05-23
HUP9603428A3 (en) 1997-10-28
NO965298D0 (no) 1996-12-11
PT780390E (pt) 2002-11-29
RU2162468C2 (ru) 2001-01-27
CN1160052A (zh) 1997-09-24
EE03474B1 (et) 2001-08-15
AU7421696A (en) 1997-06-19
NZ299905A (en) 1998-09-24
SK282805B6 (sk) 2002-12-03
RO119782B1 (ro) 2005-03-30
BG101043A (en) 1998-04-30
NL300109I1 (nl) 2003-02-03
PL184885B1 (pl) 2003-01-31
NO306725B1 (no) 1999-12-13
TR199600970A2 (tr) 1997-06-21
AR005009A1 (es) 1999-04-07
CZ288657B6 (cs) 2001-08-15
NO965298L (no) 1997-06-13
CN1061348C (zh) 2001-01-31
MX9606325A (es) 1997-10-31
CU22774A3 (es) 2002-07-24
KR970042550A (ko) 1997-07-24
IL119795A (en) 1998-12-27
SV1996000109A (es) 1997-10-23
IN185805B (enFirst) 2001-05-05
SI0780390T1 (en) 2002-10-31
CA2192418A1 (en) 1997-06-13
ZA9610405B (en) 1997-06-23
JP4104687B2 (ja) 2008-06-18
CZ364696A3 (en) 1997-07-16
EP0780390A1 (de) 1997-06-25
HU226521B1 (en) 2009-03-30

Similar Documents

Publication Publication Date Title
MA24342A1 (fr) Nouvelle modification du cristal de cdch, procede pour sa preparation et formules pharmaceutiques comprenant cette modification
MA23942A1 (fr) Formulation nouvelle contenant de la paroxetine, et procede pour sa preparation
EP0888053A4 (en) METHOD FOR TREATING CANCER AND INFECTIOUS DISEASES AND COMPOSITIONS THAT CAN BE USED THEREFOR
FI942076L (fi) Sappihappojohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkaaineina
HUP9801836A2 (hu) Guaninszármazékok és eljárás ezek előállítására
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
FR2742148B1 (fr) Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FI942077A7 (fi) Monomeerisiä sappihappojohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina
EP0727429A3 (en) Process for the preparation of molybdenum oxysulfide dithiocarbamate
IS3662A7 (is) Nýjar króman og thíókróman afleiður
NO306400B1 (no) N-substituerte azabicykloheptan-derivater, anvendelse derav og farmasöytisk preparat
FR2627296B1 (fr) Appareil pour indiquer l'heure, du type analogique
NO961797D0 (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
MA26522A1 (fr) Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes.
EE9600109A (et) a-amino- ja tsüklopentaan-ß-aminohapet(-happeid) ja/või nende derivaate sisaldavad segud ja dipeptiidid, dipeptiidide valmistamismeetod ning nimetatud segusid ja/või dipeptiide sisaldavad ravimid
TNSN99124A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de la faiblesse musculosquelettique et procede pour leur preparation.
MA23953A1 (fr) Procede nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites
BR9501921A (pt) Composto processo para sua preparação medicamento uso e método para inibir a atividade biológica do leucotrieno
ES2137665T3 (es) Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
ATE170527T1 (de) Phosphonobernsteinsäurederivate und ihre verwendung als arzneimittel
FR2738740B1 (fr) Nouveau procede pour la deformation permanente des matieres keratiniques
NO962809D0 (no) Fremgangsmåte for fremstilling av N-substituerte 4-ketoprolinderivater
FR2642760B1 (fr) Procede pour la preparation de primycine et compositions pharmaceutiques la contenant
BR1100876A (pt) Utilização do fumagilol e de seus derivados para antiinfectantes intestinais e composição farmacêutica
FR2661831B1 (fr) Formules pharmaceutiques pour le traitement des maladies vasculaires peripheriques.